Telefon:
+49 (0)241 95 163 153
Fax:
+49 (0)241 95 163 155
E-Mail:
orders@antikoerper-online.de

Rekombinanter Interleukin enhancer-binding factor 3 (ILF3) Antikörper

Der Kaninchen Monoklonal anti-Interleukin enhancer-binding factor 3 Antikörper wird verwendet zum Nachweis von Interleukin enhancer-binding factor 3 in Proben von Human, Maus und Ratte. Er wurde validiert für WB, IHC, IF und FACS.
Produktnummer ABIN7828328
328,90 €
Zzgl. Versandkosten 20,00 € und MwSt
50 μL
Lieferung nach: Deutschland
Lieferung in 9 bis 13 Werktagen

Kurzübersicht für Rekombinanter Interleukin enhancer-binding factor 3 (ILF3) Antikörper (ABIN7828328)

Target

Alle Interleukin enhancer-binding factor 3 (ILF3) Antikörper anzeigen
Interleukin enhancer-binding factor 3 (ILF3)

Antikörpertyp

Recombinant Antibody

Reaktivität

  • 72
  • 50
  • 37
  • 13
  • 11
  • 11
  • 10
  • 5
  • 5
  • 5
  • 2
  • 2
  • 1
  • 1
Human, Maus, Ratte

Wirt

  • 67
  • 3
  • 1
Kaninchen

Klonalität

  • 49
  • 23
Monoklonal

Konjugat

  • 49
  • 3
  • 3
  • 3
  • 3
  • 3
  • 3
  • 3
  • 1
  • 1
Unkonjugiert

Applikation

  • 51
  • 28
  • 20
  • 20
  • 13
  • 13
  • 12
  • 8
  • 5
Western Blotting (WB), Immunohistochemistry (IHC), Immunofluorescence (IF), Flow Cytometry (FACS)

Klon

A466
  • Verwendungszweck

    Recombinant ILF3 Monoclonal Antibody

    Aufreinigung

    Protein A purified

    Immunogen

    Recombinant human ILF3 fragment

    Isotyp

    IgG, kappa
  • Applikationshinweise

    WB 1:2000-1:10000,IHC 1:100-1:500,IF 1:50,FCM 1:50-1:100

    Beschränkungen

    Nur für Forschungszwecke einsetzbar
  • Konzentration

    1 mg/mL

    Buffer

    PBS, 50 % glycerol, 0.05 % Proclin 300, 0.05 % protein protectant.

    Konservierungsmittel

    ProClin

    Vorsichtsmaßnahmen

    This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

    Lagerung

    -20 °C

    Informationen zur Lagerung

    Store at -20°C Valid for 12 months. Avoid freeze / thaw cycles.

    Haltbarkeit

    12 months
  • Target

    Interleukin enhancer-binding factor 3 (ILF3)

    Andere Bezeichnung

    ILF3

    Hintergrund

    ILF,MMP,Mpp,DRBP,NF-AT,MPHOSPH,TCP,ILF3,CBTF,DRBF,DRBP76,MMP4,MPHOSPH4,MPP4,NF-AT-90,NF110,NF110b,NF90,NF90a,NF90b,NFAR,NFAR-1,NFAR2,TCP110,TCP80,Double stranded RNA binding protein 76,Double-stranded RNA-binding protein 76,Interleukin enhancer binding factor 3,Interleukin enhancer-binding factor 3,M phase phosphoprotein 4,M-phase phosphoprotein 4,NF AT 90,Nuclear factor associated with dsRNA,Nuclear factor of activated T cells 90 kDa,Nuclear factor of activated T-cells 90 kDa,Translational control protein 80,Interleukin enhancer-binding factor 3 (ILF3) is a double-stranded RNA (dsRNA) binding protein that complexes with other proteins, dsRNAs, small noncoding RNAs, and mRNAs to regulate gene expression and stabilize mRNAs. This protein (NF90, ILF3) forms a heterodimer with a 45 kDa transcription factor (NF45, ILF2) required for T-cell expression of interleukin 2. This complex has been shown to affect the redistribution of nuclear mRNA to the cytoplasm. Knockdown of NF45 or NF90 protein retards cell growth, possibly by inhibition of mRNA stabilization. In contrast, an isoform (NF110) of this gene that is predominantly restricted to the nucleus has only minor effects on cell growth when its levels are reduced. Alternative splicing results in multiple transcript variants encoding distinct isoforms. ILF3 exists main two isoforms NFAR-1 (90 kDa) and -2 (110 kDa). Upon viral infection, ILF3 accumulates in the cytoplasm and participates in the innate antiviral response. Cat.No. Product Name Clone No. IF:{{item.impact}} Journal:{{item.journal}} ({{item.year}}) DOI:{{item.doi}} Reactivity:{{item.species}} Sample Type:{{item.sample_type}} Previous {{ page }} Next Q{{(FAQpage.currentPage - 1)*pageSize+index+1}}:{{item.name}} Previous {{ page }} Next [

    Molekulargewicht

    Calculated MW: 95 kDa

    Observed MW: 90,110 kDa The actual band is not consistent with the expectation.

    UniProt

    Q12906

    Pathways

    M Phase
Sie sind hier:
Chat with us!